Company Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
3.54 ^USD	+1.72%		+14.19%	-19.55%

04-09	Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	CI
04-04	Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	CI

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Companyâs second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Number of employees: 17

Managers	Title	Age	Since
Stephen Brady CEO	Chief Executive Officer	54	31/08/19
Nicholas Maestas DFI	Director of Finance/CFO	44	11/07/21
Darrin Bomba CTO	Chief Tech/Sci/R&D Officer	-	30/11/21
Sam Whiting CTO	Chief Tech/Sci/R&D Officer	58	31/10/20
Justin Trojanowski AUD	Comptroller/Controller/Auditor	36	31/05/22
Sharon Sakai LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Christine Pellizzari BRD	Director/Board Member	56	30/06/21
Geoffrey Nichol BRD	Director/Board Member	69	30/11/19
Mike Raab Raab CHM	Chairman	59	31/12/20
Ronit Simantov BRD	Director/Board Member	59	05/08/21
Stephen Brady CEO	Chief Executive Officer	54	31/08/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	22,217,265	22,203,364 ( 99.94 %)	0	99.94 %

Name	Equities	%	Valuation
Versant Venture Management LLC 19.35 %	4,295,055	19.35 %	17 M $
Stella Xu 2.612 %	579,710	2.612 %	2 M $
BlackRock Institutional Trust Co. NA 2.293 %	508,928	2.293 %	2 M $
Impresa Management LLC 1.946 %	431,932	1.946 %	2 M $
Vanguard Global Advisers LLC 0.7939 %	176,193	0.7939 %	688 915 $
EAM Investors LLC 0.6322 %	140,300	0.6322 %	548 573 $
FIL Ltd. (Subfiler) 0.5839 %	129,579	0.5839 %	506 654 $
Geode Capital Management LLC 0.5674 %	125,918	0.5674 %	492 339 $
Thomas Dubensky 0.5107 %	113,343	0.5107 %	443 171 $
Ikarian Capital LLC 0.4758 %	105,600	0.4758 %	412 896 $

Tempest Therapeutics, Inc.

2000 Sierra Point Parkway Suite 400

94005, Brisbane

http://www.tempesttx.com

address Tempest Therapeutics, Inc.(TPST)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.54 USD

Average target price

18.6 USD

Spread / Average Target

+425.42%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TEMPEST THERAPEUTICS, INC.	-19.55%	78.65M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research